Optune Gio

Brand: Novocore

"Tumor treating fields (TTFields) are a non-invasive antimitotic therapy that delivers alternating electric fields via the Optune^® system. The Phase III EF-14 trial in newly diagnosed glioblastoma multiforme (GBM) showed significantly improved progression-free, overall and long-term survival when Optune was used together with maintenance temozolomide (TMZ) compared with TMZ alone. Compliance (average monthly use) was associated with better clinical outcome. The first-generation Optune system weighed approximately 6 pounds (~2.7 kg). The second-generation redesigned Optune system weighs 2.7 pounds (~1.2 kg). We tested and compared GBM patient experience with the second-generation system versus the first-generation system."^{[Kinzel, Adrian]}

Ependymoma

• Trial: Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NF1: Glioma

1. Optune. https://www.optunegio.com
2. YouTube. "Optune for Glioblastoma Multiforme (GBM)"
3. Kinzel, Adrian, et al. "Tumor treating fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation Optune^® system." Clinical Medicine Insights: Oncology 13 (2019): 1179554918825449. DOI: https://doi.org/10.1177/1179554918825449 | Source: https://journals.sagepub.com/doi/full/10.1177/1179554918825449